HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 4 (2007), Issue 9 (September)

1. Structural features and anti-HIV-1 activity of novel polysaccharides from red algae Grateloupia longifolia and Grateloupia filicina.
   Int J Biol Macromol, 41(4): 369-75. [Abstract] [Full-text]
2. Modeling HIV quasispecies evolutionary dynamics.
   BMC Evol Biol, 7: S5. [Abstract] [Full-text]
3. Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART.
   PLoS Pathog, 3(8): e122. [Abstract] [Full-text]
4. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
   PLoS Pathog, 3(8): e117. [Abstract] [Full-text]
5. Outcomes of dosage adjustments used to manage antiretroviral drug interactions.
   Clin Infect Dis, 45(7): 933-6. [Abstract] [Full-text]
6. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
   Clin Infect Dis, 45(7): 925-32. [Abstract] [Full-text]
7. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care.
   Clin Infect Dis, 45(7): 918-24. [Abstract] [Full-text]
8. Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis.
   Clin Infect Dis, 45(7): 908-15. [Abstract] [Full-text]
9. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study.
   Clin Infect Dis, 45(7): e82-7. [Abstract] [Full-text]
10. Fc receptor but not complement binding is important in antibody protection against HIV.
    Nature, 449(7158): 101-4. [Abstract] [Full-text]
11. Cesarean delivery for HIV-infected women: recommendations and controversies.
    Am J Obstet Gynecol, 197(3): S96-100. [Abstract] [Full-text]
12. Toward elimination of perinatal human immunodeficiency virus transmission in the United States: effectiveness of funded prevention programs, 1999-2001.
    Am J Obstet Gynecol, 197(3): S90-5. [Abstract] [Full-text]
13. Approaches for scaling up human immunodeficiency virus testing and counseling in prevention of mother-to-child human immunodeficiency virus transmission settings in resource-limited countries.
    Am J Obstet Gynecol, 197(3): S83-9. [Abstract] [Full-text]
14. Rapid human immunodeficiency virus-1 testing on labor and delivery in 17 US hospitals: the MIRIAD experience.
    Am J Obstet Gynecol, 197(3): S72-82. [Abstract] [Full-text]
15. Infant human immunodeficiency virus diagnosis in resource-limited settings: issues, technologies, and country experiences.
    Am J Obstet Gynecol, 197(3): S64-71. [Abstract] [Full-text]
16. Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter?
    Am J Obstet Gynecol, 197(3): S56-63. [Abstract] [Full-text]
17. International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update.
    Am J Obstet Gynecol, 197(3): S42-55. [Abstract] [Full-text]
18. Use of enhanced perinatal human immunodeficiency virus surveillance methods to assess antiretroviral use and perinatal human immunodeficiency virus transmission in the United States, 1999-2001.
    Am J Obstet Gynecol, 197(3): S33-41. [Abstract] [Full-text]
19. Reducing the risk of mother-to-child human immunodeficiency virus transmission: past successes, current progress and challenges, and future directions.
    Am J Obstet Gynecol, 197(3): S3-9. [Abstract] [Full-text]
20. Recommendations for human immunodeficiency virus screening, prophylaxis, and treatment for pregnant women in the United States.
    Am J Obstet Gynecol, 197(3): S26-32. [Abstract] [Full-text]
21. Utility of antenatal HIV surveillance data to evaluate prevention of mother-to-child HIV transmission programs in resource-limited settings.
    Am J Obstet Gynecol, 197(3): S17-25. [Abstract] [Full-text]
22. Consultation needs in perinatal HIV care: experience of the National Perinatal HIV Consultation Service.
    Am J Obstet Gynecol, 197(3): S137-41. [Abstract] [Full-text]
23. The missing link: documentation of recognized maternal human immunodeficiency virus infection in exposed infant birth records, 24 United States jurisdictions, 1999-2003.
    Am J Obstet Gynecol, 197(3): S132-6. [Abstract] [Full-text]
24. Young, seropositive, and pregnant: epidemiologic and psychosocial perspectives on pregnant adolescents with human immunodeficiency virus infection.
    Am J Obstet Gynecol, 197(3): S123-31. [Abstract] [Full-text]
25. Prevention of human immunodeficiency virus-1 transmission to the infant through breastfeeding: new developments.
    Am J Obstet Gynecol, 197(3): S113-22. [Abstract] [Full-text]
26. Site-specific interventions to improve prevention of mother-to-child transmission of human immunodeficiency virus programs in less developed settings.
    Am J Obstet Gynecol, 197(3): S107-12. [Abstract] [Full-text]
27. Prevention of mother-to-child transmission services as a gateway to family-based human immunodeficiency virus care and treatment in resource-limited settings: rationale and international experiences.
    Am J Obstet Gynecol, 197(3): S101-6. [Abstract] [Full-text]
28. Recent trends in the incidence and morbidity that are associated with perinatal human immunodeficiency virus infection in the United States.
    Am J Obstet Gynecol, 197(3): S10-6. [Abstract] [Full-text]
29. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types.
    Arch Intern Med, 167(16): 1782-90. [Abstract] [Full-text]
30. Response to region of difference 1 (RD1) epitopes in human immunodeficiency virus (HIV)-infected individuals enrolled with suspected active tuberculosis: a pilot study.
    Clin Exp Immunol, 150(1): 91-8. [Abstract] [Full-text]
31. Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study.
    Int J Drug Policy, 18(5): 447-51. [Abstract] [Full-text]
32. The Jailbreak Health Project--incorporating a unique radio programme for prisoners.
    Int J Drug Policy, 18(5): 444-6. [Abstract] [Full-text]
33. HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management.
    Int J Drug Policy, 18(5): 426-32. [Abstract] [Full-text]
34. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
    Int J Drug Policy, 18(5): 417-25. [Abstract] [Full-text]
35. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran.
    Int J Drug Policy, 18(5): 359-63. [Abstract] [Full-text]
36. Global estimates of prevalence of HCV infection among injecting drug users.
    Int J Drug Policy, 18(5): 352-8. [Abstract] [Full-text]
37. The three transfer RNAs occupying the A, P and E sites on the ribosome are involved in viral programmed -1 ribosomal frameshift.
    Nucleic Acids Res, 35(16): 5581-92. [Abstract] [Full-text]
38. Prednisolone mediated suppression of HIV-1 viral load strongly correlates with C-C chemokine CCL2: In vivo and in vitro findings.
    Clin Immunol, 125(1): 1-4. [Abstract] [Full-text]
39. Low CD4 T-cell counts despite low levels of circulating HIV: insights from the comparison of HIV-1 infected patients with a discordant response to antiretroviral therapy to patients with untreated advanced HIV-2 disease.
    Clin Immunol, 125(1): 67-75. [Abstract] [Full-text]
40. Endoribonuclease-prepared short interfering RNAs induce effective and specific inhibition of human immunodeficiency virus type 1 replication.
    J Virol, 81(19): 10680-6. [Abstract] [Full-text]
41. Transduction of human immunodeficiency virus type 1 vectors lacking encapsidation and dimerization signals.
    J Virol, 81(19): 10687-98. [Abstract] [Full-text]
42. Vpr is required for efficient Nef expression from unintegrated human immunodeficiency virus type 1 DNA.
    J Virol, 81(19): 10515-23. [Abstract] [Full-text]
43. Primary isolates of human immunodeficiency virus type 1 are usually dominated by the major variants found in blood.
    J Virol, 81(19): 10232-41. [Abstract] [Full-text]
44. N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization.
    J Virol, 81(19): 10769-76. [Abstract] [Full-text]
45. Unequal evolutionary rates in the human immunodeficiency virus type 1 (HIV-1) pandemic: the evolutionary rate of HIV-1 slows down when the epidemic rate increases.
    J Virol, 81(19): 10625-35. [Abstract] [Full-text]
46. Deficient in vitro anti-mycobacterial immunity despite successful long-term highly active antiretroviral therapy in HIV-infected patients with past history of tuberculosis infection or disease.
    Clin Immunol, 125(1): 60-6. [Abstract] [Full-text]
47. DDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-induced G2 arrest.
    J Virol, 81(19): 10822-30. [Abstract] [Full-text]
48. Modulation of retroviral restriction and proteasome inhibitor-resistant turnover by changes in the TRIM5alpha B-box 2 domain.
    J Virol, 81(19): 10362-78. [Abstract] [Full-text]
49. Although macrophage-tropic simian/human immunodeficiency viruses can exhibit a range of pathogenic phenotypes, a majority of isolates induce no clinical disease in immunocompetent macaques.
    J Virol, 81(19): 10669-79. [Abstract] [Full-text]
50. Intra-abdominal co-infection with Mycobacterium bovis and Actinomyces in an AIDS patient: the first reported case and review.
    J Infect, 55(4): e115-8. [Abstract] [Full-text]
51. Rapid diagnosis of pneumococcal pneumonia among HIV-infected adults with urine antigen detection.
    J Infect, 55(4): 300-9. [Abstract] [Full-text]
52. Use of stigma, fear, and denial in development of a framework for prevention of HIV/AIDS in rural African American communities.
    Fam Community Health, 30(4): 318-27. [Abstract] [Full-text]
53. Effects of vpu start-codon mutations on human immunodeficiency virus type 1 replication in macrophages.
    J Gen Virol, 88: 2780-92. [Abstract] [Full-text]
54. Increased human immunodeficiency virus type 1 Env expression and antibody induction using an enhanced alphavirus vector.
    J Gen Virol, 88: 2774-9. [Abstract] [Full-text]
55. Evolving clinical strategies for transplantation in the HIV-positive recipient.
    Transplantation, 84(5): 563-71. [Abstract] [Full-text]
56. Mining complex genotypic features for predicting HIV-1 drug resistance.
    Bioinformatics, 23(18): 2455-62. [Abstract] [Full-text]
57. Protein electrophoresis and immunoglobulin analysis in HIV-infected patients.
    Am J Clin Pathol, 128(4): 596-603. [Abstract] [Full-text]
58. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.
    Virology, 366(2): 245-62. [Abstract] [Full-text]
59. Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.
    Virology, 366(2): 433-45. [Abstract] [Full-text]
60. Functional interplay between the B-box 2 and the B30.2(SPRY) domains of TRIM5alpha.
    Virology, 366(2): 234-44. [Abstract] [Full-text]
61. Fifteen years of env C2V3C3 evolution in six individuals infected clonally with human immunodeficiency virus type 1.
    J Med Virol, 79(11): 1629-39. [Abstract] [Full-text]
62. Favorable outcome of ex-vivo purging of monocytes after the reintroduction of treatment after interruption in patients infected with multidrug resistant HIV-1.
    J Med Virol, 79(11): 1640-9. [Abstract] [Full-text]
63. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    J Med Virol, 79(11): 1617-28. [Abstract] [Full-text]
64. Virological and clinical aspects of HBV-HCV coinfection in HIV positive patients.
    J Med Virol, 79(11): 1679-85. [Abstract] [Full-text]
65. Adverse effects of highly active antiretroviral therapy in developing countries.
    Clin Infect Dis, 45(8): 1093-101. [Abstract] [Full-text]
66. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.
    Clin Infect Dis, 45(8): 1085-92. [Abstract] [Full-text]
67. Ten-year predicted coronary heart disease risk in HIV-infected men and women.
    Clin Infect Dis, 45(8): 1074-81. [Abstract] [Full-text]
68. Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial.
    Clin Infect Dis, 45(8): 1062-70. [Abstract] [Full-text]
69. Assessment of bacille Calmette-Guérin vaccine reaction in HIV-exposed Thai infants.
    Clin Infect Dis, 45(8): 1016-8. [Abstract] [Full-text]
70. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection.
    Clin Infect Dis, 45(8): 969-74. [Abstract] [Full-text]
71. Urolithiasis in HIV-positive patients treated with atazanavir.
    Clin Infect Dis, 45(8): e105-8. [Abstract] [Full-text]
72. Evaluation of a multiplex human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus nucleic acid testing assay to detect viremic blood donors in northern Thailand.
    Transfusion, 47(10): 1803-8. [Abstract] [Full-text]
73. Comparison of two automated nucleic acid testing systems for simultaneous detection of human immunodeficiency virus and hepatitis C virus RNA and hepatitis B virus DNA.
    Transfusion, 47(10): 1783-93. [Abstract] [Full-text]
74. Surgical intervention for HIV related vascular disease.
    Eur J Vasc Endovasc Surg, 34(4): 390-6. [Abstract] [Full-text]
75. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.
    J Biol Chem, 282(39): 28709-20. [Abstract] [Full-text]
76. Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens.
    Virology, 367(1): 175-86. [Abstract] [Full-text]
77. Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia.
    Virology, 367(1): 222-34. [Abstract] [Full-text]
78. Differential functional phenotypes of two primary HIV-1 strains resulting from homologous point mutations in the LLP domains of the envelope gp41 intracytoplasmic domain.
    Virology, 367(1): 102-16. [Abstract] [Full-text]
79. Induction of potent local cellular immunity with low dose X4 SHIV(SF33A) vaginal exposure.
    Virology, 367(1): 196-211. [Abstract] [Full-text]
80. The ability of multimerized cyclophilin A to restrict retrovirus infection.
    Virology, 367(1): 19-29. [Abstract] [Full-text]
81. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment.
    Neurology, 69(13): 1314-21. [Abstract] [Full-text]
82. Outcomes after orthotopic liver transplantation in 15 HIV-infected patients.
    Transplantation, 84(6): 697-705. [Abstract] [Full-text]
83. Black-White mortality from HIV in the United States before and after introduction of highly active antiretroviral therapy in 1996.
    Am J Public Health, 97(10): 1884-92. [Abstract] [Full-text]
84. Factors related to HIV disclosure in 2 South African communities.
    Am J Public Health, 97(10): 1775-81. [Abstract] [Full-text]
85. Assessment of a medical outreach program to improve access to HIV care among marginalized individuals.
    Am J Public Health, 97(10): 1758-61. [Abstract] [Full-text]
86. The utilization of testing and counseling for HIV: a review of the social and behavioral evidence.
    Am J Public Health, 97(10): 1762-74. [Abstract] [Full-text]
87. The effect of social support on mental and behavioral outcomes among adolescents with parents with HIV/AIDS.
    Am J Public Health, 97(10): 1820-6. [Abstract] [Full-text]
88. Discovery of human immunodeficiency virus infection by immunohistochemistry on lymph node biopsies from patients with unexplained follicular hyperplasia.
    Am J Surg Pathol, 31(10): 1534-8. [Abstract] [Full-text]
89. Scaling-up co-trimoxazole prophylaxis in HIV-exposed and HIV-infected children in high HIV-prevalence countries.
    Lancet Infect Dis, 7(10): 686-93. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.